How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

Dintsios, Charalabos-Markos; Chernyak, Nadja

doi:10.1007/s40258-021-00712-x

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For drugs with an additional benefit, the pharmaceutical company and GKV-SV agree on a negotiated price i.e. intended to reflect the ‘value’ of the drug for the corresponding patient population (Lauenroth and Stargardt, 2017; Gandjour et al ., 2020; Dintsios and Chernyak, 2022). Drugs without proven additional benefit are strictly capped in price or placed in a ‘fixed reference price group’ with comparable drugs for which a fixed amount (upper reimbursement limit) already applies (Lauenroth and Stargardt, 2017).…”

Section: Introductionmentioning

confidence: 99%

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Kleining,

Laufenberg,

Thrun

et al. 2023

HEPL

View full text Add to dashboard Cite

Introduction Since 2011, the prices for all new drugs in Germany are negotiated based on a benefit assessment. The purpose of this study was to analyze the price regulation of drugs with unproven additional benefit. Methods Benefit assessment procedures from 2011 to 2020 were reviewed and selected through AMNOG Monitor and Lauer Taxe. Negotiated annual therapy costs, the annual costs of the most cost-efficient appropriate comparative therapy (ACT) and the potential budget impact for 33 included procedures were calculated. Results 55% of the included drugs achieved a negotiated price higher than the most cost-efficient ACT, 3% were identified as equal and 42% showed lower negotiated prices. The potential savings exceeded expenditures by around EUR 523.5 m. After price flexibility was adopted by the legislator in 2017, the overall potential savings still outweighed the expenditures by around EUR 62 m. Conclusions Our analysis shows that making price negotiations more flexible by law does not undermine the fundamental aim of the AMNOG, which is to avoid additional expenditure without increased patient benefit. The regulation can thus fulfill the objective provided by the legislature of keeping drugs without proven additional benefits in the German healthcare system.

show abstract